Halozyme Therapeutics, Inc. $HALO Shares Sold by Cary Street Partners Financial LLC

Cary Street Partners Financial LLC reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 80.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 20,690 shares of the biopharmaceutical company’s stock after selling 84,291 shares during the period. Cary Street Partners Financial LLC’s holdings in Halozyme Therapeutics were worth $1,517,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in HALO. Empowered Funds LLC purchased a new position in shares of Halozyme Therapeutics in the 1st quarter valued at about $755,000. Acadian Asset Management LLC acquired a new position in Halozyme Therapeutics during the first quarter worth about $195,000. Asset Management One Co. Ltd. purchased a new position in Halozyme Therapeutics in the second quarter valued at about $98,000. AlphaQuest LLC lifted its position in shares of Halozyme Therapeutics by 2,933.1% during the 2nd quarter. AlphaQuest LLC now owns 5,308 shares of the biopharmaceutical company’s stock valued at $276,000 after acquiring an additional 5,133 shares during the period. Finally, Ashton Thomas Private Wealth LLC boosted its stake in shares of Halozyme Therapeutics by 64.6% during the 2nd quarter. Ashton Thomas Private Wealth LLC now owns 6,864 shares of the biopharmaceutical company’s stock worth $357,000 after acquiring an additional 2,694 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Up 0.4%

NASDAQ HALO opened at $69.53 on Friday. The firm has a market capitalization of $8.21 billion, a price-to-earnings ratio of 27.92, a PEG ratio of 0.28 and a beta of 0.97. The company has a debt-to-equity ratio of 43.89, a quick ratio of 3.66 and a current ratio of 4.66. Halozyme Therapeutics, Inc. has a one year low of $47.50 and a one year high of $82.22. The company’s 50 day moving average price is $72.62 and its 200 day moving average price is $70.63.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). The company had revenue of $451.77 million for the quarter, compared to analyst estimates of $446.13 million. Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The company’s revenue for the quarter was up 51.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.26 EPS. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 21st. The Goldman Sachs Group reissued a “sell” rating and issued a $56.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Wells Fargo & Company lifted their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a report on Tuesday, November 4th. Finally, Citizens Jmp increased their price target on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research report on Tuesday, November 4th. Six analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $78.56.

Insider Buying and Selling

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00. Following the sale, the chief executive officer directly owned 708,719 shares in the company, valued at $53,947,690.28. This trade represents a 2.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the sale, the director owned 40,123 shares in the company, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 49,398 shares of company stock worth $3,650,592. 2.40% of the stock is currently owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.